Alaunos Therapeutics, Inc.
TCRT
$1.55
-$0.02-1.27%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.00K | 3.00K | 5.00K | 6.00K | 6.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.00K | 3.00K | 5.00K | 6.00K | 6.00K |
| Cost of Revenue | 1.65M | 1.44M | 1.36M | 915.00K | 589.00K |
| Gross Profit | -1.64M | -1.44M | -1.36M | -909.00K | -583.00K |
| SG&A Expenses | 2.42M | 2.71M | 2.87M | 3.16M | 3.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.06M | 4.15M | 4.23M | 4.08M | 4.04M |
| Operating Income | -4.06M | -4.15M | -4.23M | -4.07M | -4.04M |
| Income Before Tax | -4.01M | -4.11M | -4.18M | -4.03M | -3.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.01 | -4.11 | -4.18 | -4.03 | -3.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.01M | -4.11M | -4.18M | -4.03M | -3.99M |
| EBIT | -4.06M | -4.15M | -4.23M | -4.07M | -4.04M |
| EBITDA | -4.04M | -4.13M | -4.22M | -4.07M | -4.03M |
| EPS Basic | -1.87 | -2.10 | -2.26 | -2.29 | -2.46 |
| Normalized Basic EPS | -1.14 | -1.29 | -1.38 | -1.43 | -1.54 |
| EPS Diluted | -1.87 | -2.10 | -2.26 | -2.29 | -2.46 |
| Normalized Diluted EPS | -1.14 | -1.29 | -1.38 | -1.43 | -1.54 |
| Average Basic Shares Outstanding | 8.89M | 8.13M | 7.79M | 7.06M | 6.48M |
| Average Diluted Shares Outstanding | 8.89M | 8.13M | 7.79M | 7.06M | 6.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |